Evidence map›Paper›PMID 31095686›Full record

Trial reportThe international journal of neuropsychopharmacology2019

Transcranial Magnetic Stimulation Markers of Antidepressant Treatment in Adolescents With Major Depressive Disorder.

Deniz Doruk Camsari, Charles P Lewis, Ayse Irem Sonmez, Aiswarya Laks Nandakumar, Marjorie A Gresbrink, Zafiris J Daskalakis, Paul E Croarkin

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Deniz Doruk CamsariDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.
Charles P LewisDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.
Ayse Irem SonmezDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.
Aiswarya Laks NandakumarDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.
Marjorie A GresbrinkDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.
Zafiris J DaskalakisTemerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Ontario, Canada.
Paul E CroarkinDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Glutamatergic and GABAergic Biomarkers in rTMS for Adolescent DepressionR01MH113700 · NIMH · MAYO CLINIC ROCHESTER · PI CROARKIN, PAUL E · 2017 to 2021
$2.5M
Glutamate Probes in Adolescent DepressionK23MH100266 · NIMH · MAYO CLINIC ROCHESTER · PI CROARKIN, PAUL E · 2014 to 2017
$685k
NCATS NIH HHS UL1 TR002377NIMH NIH HHS K23 MH100266NIMH NIH HHS R01 MH113700
6 · The paper itself

Abstract

backgroundThe goal of this study was to examine baseline transcranial magnetic stimulation measures of cortical inhibition and excitability in depressed patients and characterize their longitudinal posttreatment changes.

methodsFifteen adolescents (age 13-17 years) with moderate to severe major depressive disorder and 22 healthy controls (age 9-17) underwent single- and paired-pulse transcranial magnetic stimulation and clinical assessments. Transcranial magnetic stimulation measures included short-interval intracortical inhibition (2 and 4 milliseconds), long-interval intracortical inhibition (100, 150, and 200 milliseconds), cortical silent period, and intracortical facilitation (10, 15, and 20 milliseconds). Ten participants with major depressive disorder initiated antidepressant treatment or had dose adjustments. These participants were reassessed after treatment. Depression symptom severity was measured with the Children's Depression Rating Scale, Revised. Robust regression modeling compared healthy and depressed adolescents at baseline. Relationships between changes in cortical inhibition and changes in depressive symptom severity were assessed in the depressed adolescents receiving antidepressant treatment.

resultsOur results revealed that at baseline, short-interval intracortical inhibition-2 was significantly reduced (Padj = .01) in depressed participants, suggesting impaired cortical inhibition compared with healthy controls. At follow-up, improvement in Children's Depression Rating Scale, Revised scores correlated with improvement in short-interval intracortical inhibition-4 amplitude (greater inhibition) after antidepressant treatment (R2 = 0.63; P = .01).

conclusionsThese results suggest that cortical inhibition measures may have promise as biomarkers in adolescents treated for depression.

Indexed as

Transcranial Magnetic StimulationAdolescentAntidepressive AgentsBrainChildFemaleFollow-Up StudiesHumansLongitudinal StudiesMajor Depressive DisorderMaleNeural InhibitionPsychiatric Status Rating ScalesSensitivity and SpecificitySeverity of Illness IndexTreatment OutcomeAntidepressive Agentsadolescentcortical inhibitionmood disorderspaired-pulse transcranial magnetic stimulationshort-interval intracortical inhibition

Identifiers

PMID31095686
PMCPMC6600470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.